Home LiteratureArticle Details
PMID: 11253130 Published · ppublish English Comparative Study Journal Article

The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).

Journal of clinical pathology ·Vol. 54 ·No. 3 ·2001-03-00 ·Pages 196-200

Clarkson KS, Sturdgess IC, Molyneux AJ

Abstract

To compare the sensitivity and staining pattern of the new immunohistochemical antibody to tyrosinase (T311) with S-100, HMB45, and the recently evaluated antibody to melan-A (A103) in a range of melanocytic lesions. Archival, formalin fixed, paraffin wax embedded sections from 50 benign and malignant melanocytic lesions were stained immunohistochemically with anti-tyrosinase, A103, S-100, and HMB45. They were scored semiquantitatively for the distribution and intensity of staining. All melanomas, with the exception of desmoplastic melanoma, showed some staining with all four antibodies. Overall, T311 and A103 showed an intermediate sensitivity compared with that of S-100 and HMB45. T311 stained most benign and malignant lesions strongly and diffusely with minimal background staining. Immunoreactivity was found to be patchy in some naevi, with weak or absent staining of the mature melanocytes. A103 showed strong and diffuse staining of all benign lesions and most melanomas with minimal background staining. S-100 was the most sensitive, with diffuse staining of most lesions, including desmoplastic and metastatic melanoma, but lacked specificity. HMB45 was the least sensitive antibody, frequently demonstrating patchy staining with absent staining in some benign naevi. S-100 remains the most sensitive marker of melanocytes. However, because of its lack of specificity, it should be used with at least one other more specific antibody. HMB45 is more specific, but lacks sensitivity; T311 is a reliable marker of melanocytes in paraffin wax embedded sections and is worth consideration for use in a staining panel, although it shows no additional benefit over A103.

MeSH Terms
Antibodies, Monoclonal/immunology Antigens, Neoplasm/analysis Biomarkers, Tumor/analysis Clinical Enzyme Tests Diagnosis, Differential Humans MART-1 Antigen Melanoma/diagnosis,secondary Melanoma-Specific Antigens Monophenol Monooxygenase/analysis,immunology Neoplasm Proteins/analysis Nevus/diagnosis S100 Proteins/analysis Sensitivity and Specificity Skin Neoplasms/diagnosis
Chemicals
Antibodies, Monoclonal Antigens, Neoplasm Biomarkers, Tumor MART-1 Antigen MLANA protein, human Melanoma-Specific Antigens Neoplasm Proteins S100 Proteins Monophenol Monooxygenase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Clarkson K S
Department of Cellular Pathology, Northampton General Hospital, Cliftonville, Northampton, UK.
Sturdgess I C
Molyneux A J
References (21)
21 references, click to expand
  1. Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in human neoplasm and normal tissues.
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(4):385-96 PMID: 6145248
  2. Molecular staging of malignant melanoma: correlation with clinical outcome.
    JAMA. 1998 Oct 28;280(16):1410-5 PMID: 9801000
  3. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.
    Am J Pathol. 1986 May;123(2):195-203 PMID: 3518473
  4. Nevus cell maturation or atrophy?
    Am J Dermatopathol. 1988 Feb;10(1):20-7 PMID: 3177822
  5. HMB-45 recognizes stimulated melanocytes.
    J Cutan Pathol. 1989 Apr;16(2):49-53 PMID: 2668355
  6. Reactivity of HMB-45 monoclonal antibody with sweat-gland tumours of the skin.
    Acta Derm Venereol. 1991;71(5):426-8 PMID: 1721759
  7. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.
    Am J Dermatopathol. 1991 Dec;13(6):543-50 PMID: 1725245
  8. Immunohistochemistry in the evaluation of melanocytic tumors.
    Semin Diagn Pathol. 1993 Feb;10(1):76-91 PMID: 8506418
  9. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.
    Am J Pathol. 1993 Dec;143(6):1579-85 PMID: 7504884
  10. Molecular characterization of the melanocyte lineage-specific antigen gp100.
    J Biol Chem. 1994 Aug 5;269(31):20126-33 PMID: 7519602
  11. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
    J Natl Cancer Inst. 1996 May 1;88(9):590-4 PMID: 8609659
  12. Detection of tyrosinase mRNA from the blood of melanoma patients.
    Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):293-6 PMID: 8722221
  13. Desmoplastic and spindle-cell malignant melanoma. An immunohistochemical study.
    Am J Surg Pathol. 1996 Dec;20(12):1489-500 PMID: 8944042
  14. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.
    Am J Surg Pathol. 1998 Jan;22(1):57-63 PMID: 9422316
  15. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
    Histopathology. 1998 Feb;32(2):139-46 PMID: 9543670
  16. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Am J Surg Pathol. 1998 May;22(5):595-602 PMID: 9591730
  17. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    J Cutan Pathol. 1998 Apr;25(4):204-9 PMID: 9609139
  18. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry.
    Int J Cancer. 1998 Aug 21;79(4):318-23 PMID: 9699521
  19. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Am J Surg Pathol. 1998 Aug;22(8):976-82 PMID: 9706977
  20. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.
    Mod Pathol. 1998 Aug;11(8):740-6 PMID: 9720502
  21. New sites of human S-100 immunoreactivity detected with monoclonal antibodies.
    Am J Clin Pathol. 1986 Feb;85(2):160-8 PMID: 2418676
Article Info
Journal
Journal of clinical pathology
Abbr.
J Clin Pathol
ISSN
0021-9746
Published
2001-03-00
Pages
196-200
Language
English
Region
England
NLM ID
0376601
PMCID
PMC1731371
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com